Regulatory news Prodotti competitors Prodotti GS 1 dicembre 2023 FDA Investigates Risk of T-cell Malignancy Following Chimeric Antigen Receptor (CAR) T cell Immunotherapies
Prodotti GS / Area Kite 8 giugno 2023 NICE technology appraisal guidance: Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over
Prodotti GS / Area Kite 22 luglio 2022 Tecartus Receives Positive CHMP Opinion in Relapsed or Refractory Acute Lymphoblastic Leukemia
